The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Official Title: An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors
Study ID: NCT05689853
Brief Summary: This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Peking Union Medical College Hospital, Beijing, Beijing, China
Name: Wenming Wu, PhD
Affiliation: Peking Union Medical College Hospital
Role: PRINCIPAL_INVESTIGATOR